Eli Lilly and Company $LLY Shares Acquired by Moran Wealth Management LLC

Moran Wealth Management LLC increased its position in Eli Lilly and Company (NYSE:LLYFree Report) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,829 shares of the company’s stock after acquiring an additional 376 shares during the period. Moran Wealth Management LLC’s holdings in Eli Lilly and Company were worth $7,662,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Elefante Mark B increased its holdings in shares of Eli Lilly and Company by 124.0% in the 2nd quarter. Elefante Mark B now owns 1,317 shares of the company’s stock worth $1,027,000 after acquiring an additional 729 shares during the period. Jag Capital Management LLC increased its holdings in shares of Eli Lilly and Company by 1.1% in the 2nd quarter. Jag Capital Management LLC now owns 24,617 shares of the company’s stock worth $19,190,000 after acquiring an additional 273 shares during the period. Cornerstone Wealth Group LLC increased its holdings in shares of Eli Lilly and Company by 1.0% in the 2nd quarter. Cornerstone Wealth Group LLC now owns 12,661 shares of the company’s stock worth $9,869,000 after acquiring an additional 128 shares during the period. Kellett Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 6.2% in the 2nd quarter. Kellett Wealth Advisors LLC now owns 275 shares of the company’s stock worth $214,000 after acquiring an additional 16 shares during the period. Finally, Community Bank N.A. increased its stake in Eli Lilly and Company by 15.5% during the 2nd quarter. Community Bank N.A. now owns 3,354 shares of the company’s stock valued at $2,615,000 after buying an additional 449 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Leerink Partners reissued a “market perform” rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. UBS Group lowered their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. Finally, Cantor Fitzgerald set a $925.00 price objective on Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $948.06.

Check Out Our Latest Stock Analysis on LLY

Eli Lilly and Company Stock Performance

Shares of LLY opened at $812.65 on Wednesday. The firm’s 50 day moving average is $744.36 and its 200-day moving average is $765.86. The stock has a market capitalization of $769.14 billion, a P/E ratio of 53.11, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business’s revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director J Erik Fyrwald bought 1,565 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.